Treatment of Chronic Hepatitis C Virus Infection in Children. A Position Paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition

Short Title:

Treatment of Chronic Hepatitis C Virus Infection in Children. A Position Paper by the Hepatology Committee of ESPGHAN

Giuseppe Indolfi¹, Loreto Hierro², Antal Dezso³, Jörg Jahnel⁴, Dominique Debray⁵, Nedim Hadzic⁶, Piotr Czubowski⁷, Girish Gupte⁸, Yael Mozer-Glassberg⁹, Wendy van der Woerd¹⁰, Françoise Smets¹¹, Henkjan J Verkade¹², Björn Fischler¹³.

¹Paediatric and Liver Unit, Meyer Children's University Hospital of Florence, Firenze, Italy, ²Pediatric Liver Service Hospital Infantil Universitario La Paz, Madrid, Spain, ³First Dept. of Paediatrics, Semmelweis University, Budapest, Hungary, ⁴Department of Pediatric and Adolescent Medicines, Medical University Graz, Auenbruggerplatz 15, Graz, Austria, ⁵Pediatric Centre, Hepatology, and Transplantation AP-HP, Hôpital Necker Enfants Malades, Paris, France, ⁶Paediatric Gastrointestinal, Liver and Nutrition Centre Variety Children's Hospital King's College Hospital NHS Foundation Trust Denmark Hill Camberwell London, ⁷The Children's Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, Warsaw, Poland, ⁸Liver Unit (Including Small Bowel Transplantation), Department of Gastroenterology and Nutrition, Birmingham Children's Hospital, Steelhouse Lane, Birmingham, B4 6NH, UK, ⁹Schneider Children's Medical Center, Israel, ¹⁰Department of Pediatric
Gastroenterology, Wilhelmina Children’s Hospital, University Medical Centre Utrecht, 3584 EA Utrecht, The Netherlands, 11UCL, Cliniques Universitaires Saint-Luc, Pediatric Gastroenterology and Hepatology, Brussels, Belgium, 12Dept of Pediatrics, Center for Liver, Digestive, and Metabolic Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 13Department of Paediatrics, Karolinska University Hospital, CLINTEC, Karolinska Institutet, Stockholm, Sweden

Conflicts of Interest and Source of Funding: GI is investigator in a Gilead Sciences-sponsored clinical trial (ClinicalTrials.gov identifier: NCT02175758). LH participated as subinvestigator in ABBVIE’s sponsored study on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir (M14-748 EudraCT 2015-000111-41). For the remaining authors, none is declared.

Corresponding author
Dr Giuseppe Indolfi.
Paediatric and Liver Unit, Meyer Children’s University Hospital of Florence.
Viale Gaetano Pieraccini 24, I-50139 Firenze, Italy.
Fax +39 055 5662400; Tel +39 055 5662480.
E-mail: giuseppe.indolfi@meyer.it

Supplemental digital content is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML text of this article on the journal’s Web site (www.jpgn.org).
Abstract

OBJECTIVES: In 2017, the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) approved the use of the fixed-dose combination of ledipasvir/sofosbuvir and of the combination of sofosbuvir and ribavirin for treatment of adolescents (12-17 years, weighing more than 35 kg) with chronic hepatitis C virus (HCV) genotype 1, 4, 5 and 6 and genotype 2 and 3 infections, respectively. Although trials with direct acting antivirals (DAAs) are ongoing for younger children, the only available treatment in US and Europe for those < 12 years is still the dual therapy of pegylated interferon (PEG IFN) and ribavirin. There is currently a lack of a systematic approach to the care of these patients. The Hepatology Committee of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) developed an evidence-based position paper for the management of chronic HCV infection in children.

METHODS: A systematic literature search and meta-analysis were performed using MEDLINE and Embase from June 1, 2007 to June 1, 2017. The approach of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) was applied to evaluate outcomes. ESPGHAN Hepatology Committee members voted on each recommendation, using the nominal voting technique.

RESULTS: The efficacy of the different DAAs combinations tested was higher, the relapse and the treatment discontinuation rates lower when compared to PEG IFN and ribavirin.

CONCLUSIONS: This position paper addresses therapeutic management issues including goals, endpoints, indications, contra-indications and the optimal treatment regimen in children with chronic HCV infection.

Key words: hepatitis C virus; treatment; children; systematic review; meta-analysis; direct acting antiviral; interferon; treatment; position paper.
What is known

- Direct-acting antiviral drugs active against hepatitis C virus (HCV) infection are highly effective and safe for treatment of adults with chronic HCV infection.
- Pegylated interferon (PEG IFN) and ribavirin are no more recommended for treatment of adults.

What is new

- The fixed-dose combination of sofosbuvir/ledipasvir and the combination of sofosbuvir and ribavirin have been recently approved for treatment of children ≥12 years or weighing >35 Kg with chronic HCV genotype 1, 4, 5 and 6 and 2 and 3 infection, respectively.
- PEG IFN and ribavirin are no more recommended for treatment of children older than 12 years of age.
Objectives

The objectives of this position paper developed by the Hepatology Committee of the ESPGHAN are: to summarize the scientific evidence regarding treatment of chronic HCV infection in children performing a systematic review and meta-analysis on the topic; to provide an extensive description of the state of the art of DAAs development in children; to assess the actual and future role of IFN-based treatments and of IFN-free DAAs combinations in the current and future dynamic clinical environment; to provide consensus and recommendations on treatment of chronic HCV infection in children.

This position paper was developed to assist paediatricians and patients in the clinical decision-making of treating children with chronic HCV infection. Furthermore, it could assist policy makers in optimizing the development of new drugs for HCV infected children.

Background

The treatment perspective for HCV-infected patients has evolved substantially with the introduction of the first DAA active against HCV in 2011. Nowadays, chronic HCV infection in adults is easy to treat. Ten different oral regimens have been licensed by EMA and the FDA for treatment of adults with chronic HCV infection (Table 1). Each of these regimens can be used for achieving high (>90%) sustained virological response rates (SVR) in 12 weeks, independently of viral genotype, stage of fibrosis and of co-infection with human immunodeficiency virus (HIV) (1-4). For certain populations, equally high SVR rates can be achieved by even shorter treatment durations, i.e. 8 weeks.

The drugs currently licensed in Europe and US for treatment of chronic HCV infection in children, with age- and weight-specific limitations are IFN, PEG IFN, ribavirin and, very recently, the fixed-dose combination of ledipasvir/sofosbuvir and sofosbuvir (Table 2). Few data are available on the paediatric use of DAAs and eight trials are ongoing (Table 3). While new treatments are expected to
be approved for paediatric use for all age groups in the near future, there is uncertainty on the currently optimal approach to treat children with chronic HCV infection. Furthermore, there is concern as the timelines for the completion of the registration studies of the new drugs for children are far off (5, 6).

**Epidemiology of HCV Infection in Children**

The seroprevalence and burden of HCV infection in children are not well established. World Health Organization (WHO) recently estimated that in 2015, 71 million persons were living with HCV infection in the world (7). No paediatric data were provided in the WHO report (7). In a previous comprehensive review of the published literature on HCV epidemiology the global paediatric prevalence of anti-HCV was estimated at 11 million with 6 million viraemic children (8). Preliminary results of a recent systematic review of HCV antibody seroprevalence in children, estimated that 13.2 (11.5-21.2) million children aged between 1 and 15 years are HCV infected worldwide (9). The prevalence of HCV was higher among children treated for malignancy, those with renal failure requiring haemodialysis and those who had undergone surgical procedures (10).

Nowadays, vertical transmission from mother to the child is the main route of acquisition of HCV in childhood (11). In high income countries, horizontal transmission through injection drug use has been described as an emerging and concerning route of acquisition of HCV in adolescents (12). On the other side, in low income countries, iatrogenic transmission and transmission through traditional practices such as scarification and circumcision could account for the higher prevalence of the infection (13).

**Natural History of HCV Infection in Children**

Following vertical transmission of HCV, in the absence of treatment, 20% of the children clear the infection spontaneously, usually in the first four years of life, while the remaining 80% develops chronic infection that persists into adulthood (14-16). Chronic HCV infection is usually asymptomatic during childhood (14, 15, 17). Mild hepatomegaly was the only clinical finding reported in 10% of the children enrolled in a large, European, multicentre, prospective study of 266
infants born to HCV-infected mothers (15). In this cohort (15) and also according to the data of the largest paediatric observational study on chronic HCV infection (14), persistently raised alanine aminotransferase levels were observed in almost 50% of the children during follow-up. Extrahepatic manifestations of the infection that are potentially severe in adults (18), are rare in children (19) with the exception of subclinical hypothyroidism and autoimmune thyroiditis, described in 11% and 5.6% of HCV-infected children, respectively (20).

To date, when compared to adults, there is only limited amount of information concerning histopathology of the liver in children with chronic HCV infection (21). A wide spectrum of findings, ranging from no histopathological abnormalities to cirrhosis, have been described (17, 22-31). The majority of the children presents a near normal liver histology after more than two decades of infection (22, 23, 25, 31). However, few children with advanced liver disease have been identified as young as three years and as early as one-year post-infection (14, 22).

Children tend to have more indolent HCV infection than adults. According to the results of the main studies on the topic, liver fibrosis slowly increases with the patient's age (17, 23, 24, 28), the duration of the infection (23-25) and the severity of histological necroinflammation (22, 23, 28-30) although some studies failed to find these associations (22, 30, 32). The risk of cirrhosis in children suffering from chronic HCV infection is 1-4% while bridging fibrosis and severe inflammation were described in about 15% (14, 15, 17, 22). Hepatocellular carcinoma is rare (14, 22) with only three cases so far described (33, 34). Co-morbidities such as malignancy, haematological diseases with iron overload and viral co-infections (HIV and HBV) as well as alcohol consumption and obesity accelerate the development of severe liver disease (22, 23).

Current Treatment for Children

Table 2 shows the drugs currently approved by the EMA and the FDA for treatment of children with chronic HCV infection, including their indications, age-specific limitations, dosage and routes of administration. The fixed-dose combination of ledipasvir/sofosbuvir and the combination of sofosbuvir and ribavirin have been approved by FDA and EMA in April and June-July 2017,
respectively. These drugs can be used for treatment of adolescents (12-17 years) weighing more than 35 kg with chronic HCV genotype 1, 4, 5 and 6 and genotype 2 and 3 infections, respectively. Children younger than 12 years in US and Europe can be treated with the dual therapy of PEG IFN α-2a or -2b and ribavirin. Children with HCV genotypes 1 or 4 infection should be treated for 48 weeks while the ones with genotypes 2 or 3 should be treated for 24 weeks (21, 35-38).

**DAAs**

DAAs are classified into several categories, based on their molecular target: NS3/4A protease inhibitors, nucleotide and non-nucleotide inhibitors of NS5B polymerase and NS5A inhibitors. The development of new combinations of DAAs is based on the concept that at least two drugs are needed in order to achieve the treatment goal of obtaining high virological response rates (>90-95%) without selecting resistant mutants (39). When the backbone of the treatment is a nucleoside NS5B inhibitor (mainly sofosbuvir), only one other drug, a NS3/4A protease inhibitor or a NS5A inhibitor, is usually required. Conversely, a non-nucleoside NS5B inhibitor should be used together with both NS3/4A protease and NS5A inhibitors.

**Standard of Care for Adults**

Regimens evaluated in clinical trials and showing excellent efficacy (SVR in >90-95% of treated patients) and good safety have been included in international guidelines. The American Association for the Study of Liver Disease (AASLD) / Infectious Disease Society of North America (ISDA) the European Association for the Study of Liver Disease (EASL) and the Asian Pacific Association for the Study of the Liver (APALS) as well as the World Health Organization (WHO) issued and continuously update treatment guidance (1-4).

A recent Cochrane Group systematic review on DAAs showed the absence of a concrete effect of DAAs therapies in adults on complications related to chronic HCV infection such as hospitalization, liver deaths and transplantations (40). Both the EASL and AASLD/ISDA highlighted significant flaws in this analysis yielding misleading conclusions (41, 42). These were mainly that the studies
included in the review were not designed to determine the long term benefits of treatment in adults which in fact could be highly significant.

Methods

Recommendations were based on evidence resulting from a systematic revision and meta-analysis of existing papers on the topic published up to June 1, 2017. Evidence was evaluated by the authors and classified as high (A), moderate (B), or low (C) quality according to the GRADE system (43). The strength of recommendations in the GRADE system was classified as outlined in Supplemental Table A (Supplemental Digital Content, http://links.lww.com/MPG/B238). These recommendations are based on currently licensed drugs and will be updated, following approval of new drug regimens by the national and European regulatory agencies.

Systematic review and meta-analysis

A systematic literature search was conducted by two researchers (G.I., B.F.) working independently, in duplicate, using multiple keywords and standardized terminology in Medline, and EMBASE dating back to June 1, 2007 up to and through June 1, 2017 as reported in the Appendix 1 (Supplemental Digital Content, http://links.lww.com/MPG/B238). The following terms were used: “hepatitis C virus”; “children”; “treatment”; and/or “interferon”; and/or “direct acting antiviral” with the limits English language, human species and ages from birth to 18 years. Conference abstracts from the 2015 to 2017 annual meetings of the European Association for the Study of Liver Disease, American Association for the Study of Liver Disease, European Society of Pediatric Gastroenterology, Hepatology and Nutrition, North American Society of Pediatric Gastroenterology, Hepatology and Nutrition and of the European Society of Paediatric Infectious Disease were also evaluated.

Eligibility

Both randomized and open-label clinical trials assessing the efficacy of PEG IFN α-2a or PEG IFN α-2b in combination with RBV or of any DAA in children and adolescents (aged 3–18 years) with HCV infection were considered eligible. Eligible clinical trials had to provide a full treatment
course to patients (48 weeks for HCV genotypes 1 and 4, or 24 weeks for HCV genotypes 2 and 3 and for DAAs 12 to 24 weeks independently of HCV genotype) and had to report the most significant data with regard to treatment (viral genotype, doses, SVR). Trials enrolling children co-infected with HIV and/or hepatitis B virus or with co-morbidities were excluded. We excluded observational or retrospective studies. Conference abstract data were excluded for IFN-based treatment as considered redundant and not affecting result of the meta-analysis, but were included for the newer DAAs combinations. The main reason for this was that some of the data available on the use of DAAs in children were up to June 1, 2017 still only available as abstracts. Abstracts were included if 1. reporting on registered clinical trials on the use of DAAs in children; 2. if the information contained was sufficiently clear and accurate to permit adequate comprehension and interpretation; and 3. if the complete description of the design of the trial was available accessing clinicaltrial.gov using the registration number. Bibliographies of all relevant articles and of published systematic reviews were evaluated.

Study Selection
Two investigators (G.I. and B.F.) working independently, in duplicate, scanned all abstracts and obtained the full text reports of records potentially meeting the inclusion criteria. After obtaining full reports of the candidate studies, the same investigators independently assessed eligibility via full text review. Where required, a third investigator provided arbitration.

Data of interest
Data were abstracted for SVR, relapse and treatment discontinuations due to a lack of virological response, virological breakthrough, or to an adverse event.

Definitions
SVR was defined as undetectable HCV RNA 12 weeks (SVR12) or 24 weeks (SVR24) after treatment completion for DAAs or IFN-based regimes, respectively. Re-appearance of HCV RNA in serum while still on therapy or after discontinuation of therapy were defined virological breakthrough and relapse, respectively.
Data Analysis

The inter-rater reliability on inclusion of articles was assessed using the phi statistic (ϕ). Pooled proportions were calculated for each data of interest using a Freeman-Tukey–type arcsine square root transformation, and applying a random-effects model. Sensitivity analyses assessed differences in the outcome of the two treatment combinations overall and by HCV genotypes (1 and 4; 2 and 3, respectively). Pooled confidence intervals for difference in proportions analyses were conducted to assess whether meaningful differences existed between these combinations. All analyses were conducted using MedCalc Statistical Software version 17.6 (MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 2017).

Results

The schematic of study selection process is provided in Figure 1, while the complete results of the searches are described in the Appendixes 2 to 5 (Supplemental Digital Content, http://links.lww.com/MPG/B238). Overall, 16 studies met the inclusion criteria (35-38, 44-55). The inter-rater reliability for study inclusion was high (ϕ = 1).

PEG IFN and ribavirin

Eleven studies reporting on combined treatment with PEG IFN and ribavirin were included. The data of interest were reported in Supplemental Table B (Supplemental Digital Content, http://links.lww.com/MPG/B238). Overall, the efficacy of this combination therapy was higher for children infected by HCV genotypes 2 and 3 (90%; Table 4 and Figure 2, panel A) than for those infected by genotypes 1 and 4 (48%; Table 4 and Figure 2, panel B). Relapse rate, independent from genotype and treatment duration, was 6% (Table 4). Treatment discontinuation was reported in 17% of the children treated (Table 4). Discontinuation due to severe adverse events occurred in 2%.

DAA

Two trials published as full-length articles and three as abstracts were included (Supplemental Table C, Supplemental Digital Content, http://links.lww.com/MPG/B238). The overall efficacy of
the different DAAs combinations tested was very high (98; Table 5 and Figure 3). Relapse rate was low (0.7%) and no treatment discontinuation was reported (Table 5).
**Goal and endpoint of HCV therapy**

Independently of the treatment strategy used (PEG IFN plus ribavirin or DAAs), the goal of therapy in children with chronic HCV infection is to cure the infection. The risk of HCV-related hepatic and extra-hepatic complications in children is significantly lower than for adults. Advanced liver disease has been described in up to 4% of children with chronic infection in very selected populations and could be prevented by curing HCV infection.

The endpoint of anti-HCV therapy is an SVR defined by undetectable HCV RNA in blood as assessed by a sensitive molecular method with a lower limit of detection (<15 IU/ml). SVR 12 weeks (SVR12) and/or 24 weeks (SVR24) after the end of treatment were used as endpoints in DAAs and in IFN-based studies, respectively. Adult data confirmed the high concordance between SVR12 and 24 (>99%) (56) and few long-term follow-up paediatric studies have shown that SVR24 corresponds to a definitive cure of HCV infection in 98% to 100% of cases (57, 58). No long-term study (beyond 24 after the end of treatment) is presently available for DAAs in children.

**Recommendation**

- *The goal of therapy in children is to cure HCV infection to prevent the possible progression of HCV-related liver disease and its complications (A1).*

- *The endpoint of therapy in children is undetectable HCV RNA in blood by a sensitive assay (lower limit of detection ≤15 IU/ml) 12 weeks (SVR12) after the end of DAAs treatment or 24 weeks (SVR24) after the end of PEG IFN and ribavirin (A1).*

**Indications for treatment: who should be treated?**

According to the currently available adult treatment guidelines (1-4) all treatment-naïve and -experienced patients with chronic HCV infection, independently of staging of liver disease, who are willing to be treated and who have no contraindications to treatment, should be considered for therapy. The timing of treatment in adult guidelines was impacted by the presence of significant fibrosis and cirrhosis, of extrahepatic manifestations or of co-morbidities increasing the risk of rapid
evolution of liver disease. Furthermore, treatment in adults is considered without delay in patients with HCV recurrence after liver transplantation and in those at risk of transmitting HCV. Adult guidelines changed significantly with the approval of the new DAAs combinations and indications for treatment are now based on the optimal safety and efficacy profiles irrespective of the costs that are the main limitation to the universal application of the new treatments.

The rationale underlying the indications for treatment of adults with chronic infection is valid also for children although the majority of them have a very mild disease and do not need urgent treatment. In adults with chronic HCV infection assessment of liver disease severity is recommended prior to therapy (1, 2). Non-invasive techniques are generally used as first line and liver biopsy is reserved for selected cases (1, 2). Staging is highly relevant for adults while it is less for children with chronic HCV infection as only a minority of them presents advanced liver disease. In children non-invasive techniques have not been validated yet and liver biopsy for obtaining liver tissue for histopathologic examination is still the gold standard procedure for assessment of liver fibrosis (59). While the presence of cirrhosis or advanced fibrosis affects the choice of the treatment regimen in adults, so far it has no effect in children where no alternative regimen is available. Liver stiffness measurement may replace in the future the use of liver histology for staging of HCV-related liver disease at least in adolescents. In the meantime, liver biopsy should be reserved for the few cases where there is suspicion of advanced liver disease, potential additional aetiologies or to confirm clinical evidence of cirrhosis (59).

Previous studies clearly demonstrated that both the physical and psychosocial health and cognitive functioning of asymptomatic children with chronic HCV infection are significantly reduced compared with children without HCV (60, 61). Moreover, caregivers were highly distressed about their children’s medical circumstances (61). Recently, it was demonstrated that adolescents treated with ledipasvir/sofosbuvir self-reported improvement of quality of life both during treatment and after achieving SVR that was confirmed by the parental assessment (62).
The cost of the new DAAs combination therapies have been an important obstacle to broader use of the treatment. The use of lower and therefore cheaper doses of DAAs in children when compared to adults could provide benefits in terms of potential cost savings. The recent data highlighting concerns about horizontal transmission of HCV infection in adolescents through injecting drug use in high income settings provide additional evidence for supporting early treatment in children before they reach the age when this risk increases (63). This could also reduce the risk of sexual transmission of the infection.

**Recommendations**

- *The rationale underlying the indications for treatment of adults with chronic infection is valid also for children (B1)*
- *We recommend that all treatment-naïve and treatment-experienced children with chronic HCV infection are considered for therapy (A1).*
- *Liver biopsy for obtaining liver tissue for histopathologic examination is not routinely indicated in children with chronic HCV infection but it should be evaluated case-to-case (A1)*
- *We recommend that treatment is considered without delay in presence of significant fibrosis and cirrhosis, extrahepatic manifestations and co-morbidities increasing the risk of rapid evolution of liver disease (solid organ or haematopoietic stem cell transplant recipients, other patients undergoing immunosuppressive treatments) (A1)*
- *Treatment can be generally deferred in age-cohorts where combined PEG IFN and ribavirin is the only treatment option (C1)*

**Approved drugs in Europe in 2017**

Two different DAAs combinations for treatment of children with chronic HCV infection have so far been approved by the EMA and FDA, namely the fixed-dose combination of ledipasvir/sofosbuvir and of sofosbuvir and ribavirin. Both therapy combinations can be used for children older than
twelve years who weigh at least 35 kg and are chronically infected by HCV genotypes 1 or 4 and 2 or 3, respectively. EMA approved the use of ledipasvir/sofosbuvir and sofosbuvir under the centralised authorisation procedure. This procedure allows pharmaceutical companies to market the medicines throughout the European Union on the basis of a single marketing authorisation although the synchronous availability of the drug in each Member State is not granted. Decisions about price and reimbursement depend on the potential role and use of the medicine in the context of the national health system and take place at a country level. The differences in the health systems across Europe together with the cost of the new drugs could result in the non-homogeneous access of DAAs in different European countries. One of the major aims of the present position paper is to assist national and international regulatory agencies in speeding up and facilitating the availability of the drugs for this specific target population.

The therapeutic superiority of the new DAAs regimens when compared with the IFN-based ones in terms of efficacy couples with the better safety profile. A detailed description of the safety profile of IFN-based therapies is available elsewhere (64). The analysis of treatment discontinuation rates both for virological non-response/breakthrough and for adverse events related to therapy confirmed the safety of DAAs and the burdensome safety profile of PEG IFN and ribavirin. It is well known that children have a better tolerance to IFN and ribavirin than adults and that the treatment discontinuation rate due to adverse events related to therapy is not a good indicator of the safety of the treatment. Both on-therapy side effects, such as flu-like symptoms including fever, decreased appetite, asthenia, and fatigue and haematological complications such as anaemia, leukopaenia and neutropaenia, and possible irreversible after-therapy side effects, such as thyroid disease, diabetes, ophthalmologic complications and impairment of growth (37, 38, 57, 65), should be considered when assessing the risk-benefit profile of PEG IFN and ribavirin therapy in children with HCV infection.

 Patients Group 1: Treatment of chronic HCV infection in adolescents
The availability of safe IFN-free regimens for adolescents older than 12 years and weighing >35 kg, makes these the best options in treatment-naïve and -experienced patients independently of the stage of liver disease and of the presence or absence of co-morbidities. Consequently, the combination of PEG IFN and ribavirin is no more recommended. The cost of the new drugs and the differences in the health systems across Europe could be responsible for the non-homogeneous use of DAAs in different countries and regions. It is hoped that the publication of the present up-to-date position paper will assist national and international regulatory agencies and industry in setting up specific reimbursement schedules and discounting drug costs for this specific target population.

**Recommendations**

- **IFN-free regimens are the best options in HCV-infected adolescents (>12 years of age, weight > 35 kg) independently of the stage of liver disease and of co-morbidities (C1).**
- **PEG IFN and ribavirin are presently no more recommended for treatment of HCV-infected adolescents since 2017 (C1).**

**Treatment of HCV genotype 1 or 4 infection**

Only the fixed dose combination of ledipasvir/sofosbuvir, is available for adolescents with HCV genotype 1 or 4 in 2017.

In the recently published registratation trial, 100 patients have been enrolled and treated with the combination of ledipasvir (90 mg) and sofosbuvir (400 mg) as a single tablet administered once daily for 12 weeks (51). This prospective, open-label, uncontrolled study included 80 treatment-naïve, one patient with and 42 without cirrhosis, respectively and 57 patients in whom the degree of fibrosis was unknown. SVR was achieved in 98% (98/100) of cases after 12 weeks of treatment. The two patients who did not achieve SVR12 were lost to follow-up, one at treatment week 4, the other after having achieved end of treatment virological response. The most commonly reported adverse events were headache (27%), diarrhea (14%) and fatigue (13%), all being reversible following the treatment completion (51). None had severe adverse events and significant abnormalities in laboratory results. No data is currently available on possible shortening of the
treatment to eight weeks as suggested in adults if their baseline HCV RNA level is below 6 million (6.8 Log) IU/ml (66). In this trial, children with HCV genotype 1 infection, who were treatment-experienced with compensated cirrhosis were supposed to be treated for 24 weeks but no child with such characteristics was enrolled. The EMA- and FDA-approved duration of therapy with ledipasvir/sofosbuvir for treatment-experienced, cirrhotic children with HCV genotype 1 infection is 24 weeks.

**Recommendation**

- We recommend that children older than 12 years who weigh > 35 kg chronically infected with HCV genotype 1 or 4, are treated with the combination of ledipasvir (90 mg)/sofosbuvir (400 mg) with a single tablet administered once daily for 12 weeks (C1). The recommended duration of therapy for treatment-experienced children with HCV genotype 1 infection and with compensated cirrhosis is 24 weeks (C2).

**Treatment of HCV genotype 2 or 3 infection**

Only one IFN-free treatment option, the association of sofosbuvir and ribavirin, is currently available for adolescents infected with HCV genotype 2 or 3. In the recently published prospective, open-label, uncontrolled registration trial, 52 patients have been enrolled and treated with sofosbuvir 400 mg once daily and weight-based ribavirin (15 mg/kg) twice daily for 12 (genotype 2) or 24 (genotype 3) weeks (52). Forty-three (83%) of the patients were treatment-naïve and 21 patients underwent liver biopsy showing the absence of cirrhosis. SVR12 was achieved in 98% (51/52) of cases and was 100% (13/13) for patients with genotype 2 and 97% (38/39) for genotype 3. The remaining patient was lost to follow-up after achieving SVR four weeks after the end of treatment and thus did not achieve SVR12. The most commonly reported reversible adverse events were nausea (27%) and headache (23%) (52).

Despite the good efficacy rate of the combined therapy with PEG IFN and ribavirin in children with chronic HCV infection (SVR24 in 90% of the children treated for 24 weeks), given the higher efficacy rate and the better safety profile of sofosbuvir and ribavirin, PEG IFN and ribavirin are no
more recommended. It should be noted that the association of sofosbuvir and ribavirin is no more considered as standard of care for treatment of adults with HCV genotype 2 or 3, since other combinations, avoiding ribavirin, are available (1-4). Hopefully, in the future until new ribavirin-free options will be available also for children substituting the association of sofosbuvir and ribavirin.

**Recommendations**

- We recommend that children older than 12 years who weigh >35 Kg chronically infected with HCV genotype 2 are treated with sofosbuvir 400 mg once daily and weight-based ribavirin (15 mg/Kg in two divided doses) for 12 weeks (C1)
- We recommend that children older than 12 years who weigh >35 Kg chronically infected with HCV genotype 3 are treated with sofosbuvir 400 mg once daily and weight-based ribavirin (15 mg/Kg in two divided doses) for 24 weeks (C1)

**Patients Group 2: Treatment of chronic HCV infection in children younger than 12 years**

No IFN-free treatment option is yet available for children younger than 12 years infected with HCV. There is uncertainty about how to manage these children. In the past, most of the children who received the therapy were treated independently of the stage of HCV-related liver damage in order to cure the infection and prevent the unpredictable progression of the disease. On the other side, the majority of the infected children did not receive treatment given the overall mild nature of HCV-related liver disease, the low efficacy of PEG IFN with ribavirin (especially for genotypes 1 and 4) and its burdensome safety profile. At present, the latter approach is even more justified, given the results of the DAAs combinations in older paediatric age cohorts and the preliminary results of the fixed-dose combination of ledipasvir/sofosbuvir in children aged 6 to 11 years (53). In this prospective, open-label, uncontrolled trial 90 patients had been enrolled and all were treated with ledipasvir (45 mg) and sofosbuvir 200 mg once daily with a single tablet administered once daily for 12 weeks, except one genotype 1 treatment-experienced cirrhotic patient and two genotype
3 patients, who received 24 weeks of therapy. Eighty-six (96%) of the patients were infected by HCV genotype 1, and two each (2%) by HCV genotype 3 and 4. Eighteen (20%) were treatment-experienced and 2 had cirrhosis. Ninety-nine percent (89/90) of the children treated achieved SVR12. One genotype 1a patient with cirrhosis relapsed at fourth follow-up visit. The most commonly reported adverse events were headache (19%), fever (17%) and abdominal pain (15%)(53).

In most cases treatment of children younger than 12 years could be postponed until the expected extension to the existing age-indication for DAAs is granted. It is possible that the treatment could be warranted in isolated cases when there is a high clinical suspicion of advanced liver disease that is confirmed by a liver biopsy showing significant fibrosis(14, 22, 23, 30). Such cases should be referred to a centre with experience in the treatment of children with chronic HCV infection and possible off-label use of DAAs should be considered.

Recommendation

- We no longer recommend PEG IFN and ribavirin as a general treatment for children younger than 12 years infected with HCV (C1)

- In children younger than 12 years the decision to initiate therapy should be individualized to isolated cases based on the HCV genotype, severity of liver disease (as assessed by liver biopsy), potential for side effects, likelihood of response and presence of co-morbidities. These cases should be referred to a centre with experience in the treatment of children with chronic HCV infection and the possible off-label use of DAAs could be considered (C1)

Treatment of special groups

No data from controlled trials are available on the use of DAAs in children with co-infections (HBV, HIV), co-morbidities (renal impairment, non-hepatic solid organ transplant recipients, children before and after liver transplantation, active drug users, patients with haemoglobinopathies and coagulation disorders) and non-sustained virological responders to DAAs. Isolated and highly
promising experiences with young children undergoing liver transplantation or with cirrhosis are available (67, 68). There is an on-going debate as to whether adults with decompensated cirrhosis without hepatocellular carcinoma awaiting liver transplantation should be treated for their HCV infection prior or after to liver transplantation. The suggested approach is to initiate treatment as soon as possible in order to complete a full treatment course before transplantation (1, 2). The positive effect of viral clearance on liver function may lead to delisting selected cases. When the patient is listed for liver transplantation and the expected waiting time is shorter than the duration of the full DAAs treatment course there is indication to make the transplant first and treat for HCV promptly after transplantation (1, 2). In adults with HCV recurrence after liver transplantation treatment with DAAs is considered without delay (1, 2). Similar approaches seem reasonable for children with decompensated cirrhosis without hepatocellular carcinoma awaiting or having undergone liver transplantation.

**Perspective of new treatments**

At least one other treatment regimen (ombitasvir/paritaprevir/ritonavir with or without dasabuvir with or without ribavirin) for children older than 12 years of age is at the clinical developmental stage. In the recently presented prospective, open-label, uncontrolled ZIRCON trial, 38 patients with HCV genotypes 1 or 4 infections were enrolled and treated with ombitasvir/paritaprevir/ritonavir (150/100/25 mg once daily) with dasabuvir (only for those with genotype 1 infection; 250 mg twice daily) and /or ribavirin (for all patients with genotype 1a or 4 infection; 15 mg/Kg divided twice daily)(54). All the patients received 12 weeks of treatment with the exception of one patient with HCV genotype 1a infection with cirrhosis who was treated for 24 weeks. Twenty-five (66%) of the patients were treatment-naïve and 37 (97%) were non-cirrhotic. All 38 patients achieved SVR12 (100%). The most commonly reported adverse events were headache (21%) and asthenia (18%) (54).
Recently, very preliminary data from a prospective, open-label, uncontrolled trial on the combined therapy with sofosbuvir, daclatasvir with or without ribavirin (400 mg + 60 mg + 15 mg/Kg) of 13 adolescents with HCV genotype 4 infection were presented. SVR was 100% (Supplemental Table C, Supplemental Digital Content, http://links.lww.com/MPG/B238) (55).

Conclusions

The fixed-dose combination ledipasvir/sofosbuvir and sofosbuvir used with ribavirin are safe and effective and are the best options for treatment of chronic HCV infection in adolescents. Despite the overall impressive results already obtained, it should be noted that the major conclusions and recommendations of the present position paper are based on a small number of trials of DAAs, all with a very short follow-up. This should be accounted for as a major limitation and the availability of more studies and of the long term follow-up data is needed to confirm the present results. However, the existing adult long term experience with DAAs is highly encouraging.

Drug development continues and these recommendations will need to be updated regularly, following approval of new drug regimens by the EMA. The next generation, ribavirin-free, DAA combinations (i.e. sofosbuvir/velpatasvir and glecaprevir/pibrentasvir) demonstrate high pan-genotypic efficacy with shorter duration of treatment whilst maintaining the highest safety profiles. This is particularly relevant for HCV genotype 3 infection where sofosbuvir and ribavirin is no more a recommended regimen in adults.

The present position paper advocates treatment of adolescents with chronic HCV infection and is directed to health authorities in order to recognize the importance of treating this special group of patients affording the cost of treatment. Chronic HCV infection has overall a benign course in children but treatment should be an integral component of the public health approach needed for success in moving towards eradication of hepatitis C.
Disclaimer

ESPGHAN is not responsible for the practices of physicians and provides guidelines and position papers as indicators of best practice only. Diagnosis and treatment is at the discretion of physicians.
References


42. Response to the Cochrane systematic review on DAA-based treatment of chronic hepatitis C. J Hepatol 2017 in press.


49. Schwarz KB, Gonzalez-Peralta RP, Murray KF, et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 2011;140:450-8.e1.


62. Younossi ZM, Stepanova M, Balistreri W, et al. High Efficacy and Significant Improvement of Quality of Life (QoL) in Adolescent Patients with Hepatitis C Genotype 1 (GT1) Treated with Sofosbuvir (SOF) and Ledipasvir (LDV). Hepatology 2016;64:A709


Figure 1. Flow chart of search results

11 conference abstracts identified and screened

594 records identified through Medline
767 records identified through Embase

- 229 records identified by both databases
+ 3 additional records identified through reference list search

1079 excluded based on abstracts

1135 abstracts screened

56 full text articles assessed for eligibility

8 excluded:
- 4 duplicate publications
- 1 non controlled trial
- 3 not focused on efficacy

16 included

43 excluded:
- 15 duplicate publications
- 2 incomplete data
- 26 not satisfying eligibility criteria
**Figure 2.** Meta-analysis results for sustained virological response in children infected with hepatitis C virus genotypes 2 and 3 (panel A) and 1 and 4 (panel B) treated with pegylated interferon and ribavirin

Note to Figure 2. The study by Schwarz et al. (49) was a prospective, randomized, controlled clinical trial; all the others were prospective, open-label and uncontrolled studies.
**Figure 3.** Meta-analysis results for sustained virological response in children infected with hepatitis C virus (all genotypes) treated with direct acting antivirals

Note to Figure 3. All the clinical trials evaluated were prospective, open-label and uncontrolled.
Figure 4: Panel: Recommendations for Treatment of Chronic HCV infection in Children

Panel: Recommendations for Treatment of Chronic HCV infection in Children

- The goal of therapy in children is to cure HCV infection to prevent the potential progression of HCV-related liver disease and its complications (A1).
- The endpoint of therapy in children is undetectable HCV RNA in blood by a sensitive assay (lower limit of detection ≤15 IU/ml) 12 weeks (SVR12) after the end of DAAs treatment or 24 weeks (SVR24) after the end of PEG IFN and ribavirin (A1).
- The rationale underlying the indications for treatment of adults with chronic infection is valid also for children (B1).
- We recommend that all treatment-naive and treatment-experienced children with chronic HCV infection are considered for therapy (A1).
- Liver biopsy for obtaining liver tissue for histopathologic examination is not routinely indicated in children with chronic HCV infection but it should be evaluated case-to-case (A1).
- We recommend that treatment is considered without delay in presence of significant fibrosis and cirrhosis, extrahepatic manifestations and co-morbidities increasing the risk of rapid evolution of liver disease (solid organ or haematopoietic stem cell transplant recipients, other patients undergoing immunosuppressive treatments) (A1).
- Treatment can be generally deferred in age-cohorts where combined PEG IFN and ribavirin is the only treatment option (C1).
- IFN-free regimens are the best options in HCV-infected adolescents (>12 years of age, weight > 35 kg) independently of the stage of liver disease and of co-morbidities (C1).
- PEG IFN and ribavirin are presently no more recommended for treatment of HCV-infected adolescents since 2017 (C1).
- We recommend that children older than 12 years who weigh > 35 kg chronically infected with HCV genotype 1 or 4, are treated with the combination of ledipasvir (90 mg)/sofosbuvir (400 mg) with a single tablet administered once daily for 12 weeks (C1). The recommended duration of therapy for treatment-experienced children with HCV genotype 1 infection and with compensated cirrhosis is 24 weeks (C2).
- We recommend that children older than 12 years who weigh > 35 kg chronically infected with HCV genotype 2 are treated with sofosbuvir 400 mg once daily and weight-based ribavirin (15 mg/kg in two divided doses) for 12 weeks (C1).
- We recommend that children older than 12 years who weigh > 35 kg chronically infected with HCV genotype 3 are treated with sofosbuvir 400 mg once daily and weight-based ribavirin (15 mg/kg in two divided doses) for 24 weeks (C1).
- We no longer recommend PEG IFN and ribavirin as a general treatment for children younger than 12 years infected with HCV (C1).
- In children younger than 12 years the decision to initiate therapy should be individualized to isolated cases based on the HCV genotype, severity of liver disease (as assessed by liver biopsy), potential for side effects, likelihood of response and presence of co-morbidities. These cases should be referred to a centre with experience in the treatment of children with chronic HCV infection and the possible off-label use of DAAs could be considered (C1).
**Table 1.** Direct acting antivirals against HCV approved by the European Medicines Agency and the Food and Drug Administration in adults (date: August 2017)

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Producing company</th>
</tr>
</thead>
<tbody>
<tr>
<td>daclatasvir</td>
<td>BMS</td>
</tr>
<tr>
<td>elbasvir/grazoprevir</td>
<td>MSD</td>
</tr>
<tr>
<td>glecaprevir/pibrentasvir</td>
<td>Abbvie</td>
</tr>
<tr>
<td>ledipasvir/sofosbuvir</td>
<td>Gilead</td>
</tr>
<tr>
<td>ombitasvir/paritaprevir/ritonavir</td>
<td>Abbvie</td>
</tr>
<tr>
<td>ombitasvir/paritaprevir/ritonavir/dasabuvir</td>
<td>Abbvie</td>
</tr>
<tr>
<td>simeprevir</td>
<td>Janssen</td>
</tr>
<tr>
<td>sofosbuvir</td>
<td>Gilead</td>
</tr>
<tr>
<td>sofosbuvir/velpatasvir</td>
<td>Gilead</td>
</tr>
<tr>
<td>sofosbuvir/velpatasvir/voxilaprevir</td>
<td>Gilead</td>
</tr>
</tbody>
</table>

**Table 2.** Drugs approved by the European Medicines Agency and the Food and Drug Administration for treatment of children with chronic HCV infection (date: August 2017)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Age (years)</th>
<th>Genotype</th>
<th>Dosage</th>
<th>Route of administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>interferon α-2b</td>
<td>3-18</td>
<td>1-6</td>
<td>$6 \times 10^6$ IU/m$^2$ 3 times a week</td>
<td>subcutaneous</td>
</tr>
<tr>
<td>pegylated interferon α-2a</td>
<td>5-18</td>
<td>1-6</td>
<td>100 μg/m$^2$ per week</td>
<td>subcutaneous</td>
</tr>
<tr>
<td>pegylated interferon α-2b</td>
<td>3-18</td>
<td>1-6</td>
<td>1.5 μg/Kg per week</td>
<td>subcutaneous</td>
</tr>
<tr>
<td>ribavirin</td>
<td>1-18</td>
<td>1-6</td>
<td>15 mg/kg per day in 2 divided doses</td>
<td>oral</td>
</tr>
<tr>
<td>sofosbuvir</td>
<td>12-17</td>
<td>2,3</td>
<td>400 mg per day</td>
<td>oral</td>
</tr>
<tr>
<td>ledipasvir/sofosbuvir</td>
<td>12-17</td>
<td>1, 4-6</td>
<td>90/400 mg per day</td>
<td>oral</td>
</tr>
</tbody>
</table>
**Table 3.** Ongoing studies with direct acting antivirals in children and adolescents with chronic HCV infection (last update September 2017)

<table>
<thead>
<tr>
<th>Combined regimens</th>
<th>Genotype</th>
<th>Identifier</th>
<th>Expected completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>glecaprevir/pibrentasvir</td>
<td>1-6</td>
<td>NCT 03067129</td>
<td>May 2022</td>
</tr>
<tr>
<td>ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin</td>
<td>1,4</td>
<td>NCT 02486406</td>
<td>Sept 2019</td>
</tr>
<tr>
<td>sofosbuvir + daclatasvir</td>
<td>4</td>
<td>NCT 03080415</td>
<td>June 2018</td>
</tr>
<tr>
<td>ledipasvir/sofosbuvir *</td>
<td>1,4</td>
<td>NCT 02868242</td>
<td>April 2019</td>
</tr>
<tr>
<td>ledipasvir/sofosbuvir + ribavirin</td>
<td>1,4,5,6</td>
<td>NCT 02249182</td>
<td>July 2018</td>
</tr>
<tr>
<td>sofosbuvir + ribavirin</td>
<td>2,3</td>
<td>NCT 02175758</td>
<td>April 2018</td>
</tr>
<tr>
<td>sofosbuvir/velpatasvir</td>
<td>1-6</td>
<td>NCT 03022981</td>
<td>Dec 2019</td>
</tr>
<tr>
<td>gratisovir + ribavirin</td>
<td>1-6</td>
<td>NCT 02985281</td>
<td>June 2018</td>
</tr>
</tbody>
</table>

Note: * Egyptian children undergoing cancer chemotherapy

**Table 4.** Random-effects proportional meta-analysis of the data of interest assessed for children treated with pegylated interferon and ribavirin

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Proportion (95% confidence interval)</th>
<th>Number of arms</th>
</tr>
</thead>
<tbody>
<tr>
<td>sustained virological response</td>
<td></td>
<td></td>
</tr>
<tr>
<td>genotypes 1 and 4</td>
<td>48.6 (44.1-53.1)</td>
<td>11</td>
</tr>
<tr>
<td>genotypes 2 and 3</td>
<td>90.9 (84.2-95.9)</td>
<td>7</td>
</tr>
<tr>
<td>relapse</td>
<td>6.1 (2.8-10.5)</td>
<td>10</td>
</tr>
<tr>
<td>virologic breakthrough</td>
<td>3.4 (0.8-7.7)</td>
<td>8</td>
</tr>
<tr>
<td>treatment discontinuation</td>
<td>17.7 (6.4-33.2)</td>
<td>9</td>
</tr>
<tr>
<td>due to lack of virologic response</td>
<td>14.9 (15.3-29.3)</td>
<td>9</td>
</tr>
<tr>
<td>due to an adverse event</td>
<td>2.4 (1.1-4.3)</td>
<td>11</td>
</tr>
</tbody>
</table>

**Table 5.** Random-effects proportional meta-analysis of the data of interest assessed for children treated with direct acting antivirals

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Proportion (95% confidence interval)</th>
<th>Number of arms</th>
</tr>
</thead>
<tbody>
<tr>
<td>sustained virological response</td>
<td>98.1 (96.2-99.3)</td>
<td>5</td>
</tr>
<tr>
<td>genotypes 1 and 4</td>
<td>98.2 (96.2-99.5)</td>
<td>4</td>
</tr>
<tr>
<td>genotypes 2 and 3</td>
<td>96.9 (90.9-99.8)</td>
<td>2</td>
</tr>
<tr>
<td>relapse</td>
<td>0.7 (0.08-1.9)</td>
<td>5</td>
</tr>
<tr>
<td>virologic breakthrough</td>
<td>not calculable</td>
<td>5</td>
</tr>
<tr>
<td>treatment discontinuation</td>
<td>not calculable</td>
<td>5</td>
</tr>
<tr>
<td>due to lack of virologic response</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>due to an adverse event</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>